Refile: CORRECTED-Biomérieux third-quarter sales grew more than expected
REFILE-CORRECTED-Biomérieux third-quarter sales grew more than expected Refiles to remove extranenous words in paragraph 2
Nov 3 (Reuters) - French biotechnology firm Biomérieux BIOX.PA reported on Tuesday a better-than-expected organic sales growth in the third quarter, helped by a 13% increase in sales from GO 28 growth drivers.
Total sales for the period came in at €1,042 million ($1.17 billion), up 8% year on year, above the company's compiled median consensus for sales of €1,007 million and organic growth of 5.9%.
($1 = 0.8937 euros)
(Reporting by Margaux Perrin in Gdansk, editing by Izabela Niemiec)
Recent news on Biomerieux SA
See all newsBrief: Biomerieux Receives US FDA 510(K) Clearance And Ivdr CE Marking For Vitek Pro
Brief: bioMerieux Receives FDA Clearance For Latest Versions Of Biofire® Filmarray
Europe Research Roundup: Asos, Erste Group, SCHOTT pharma
Europe Research Roundup: Acceler8 Ventures, Hermes, Soitec
BioMerieux shares rise after Q3 sales beat